Our previous study found that exogenous FGF21 upregulated the PPARγ expression, inhibited hypoxia‐induced PASMC proliferation, improved pulmonary artery remodelling and reduced pulmonary artery pressure,10, 11 suggesting that FGF21 may be a promising therapeutic agent for PAH. The gene discussed is FGF21; the disease is pulmonary arterial hypertension.